Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exagen Inc (NQ: XGN )

3.160 +0.040 (+1.28%)
Streaming Delayed Price Updated: 10:11 AM EDT, Aug 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Exagen Inc

< Previous 1 2 Next >
Exagen Inc. Reports Strong Second Quarter 2024 Results: Raises Guidance due to Record Performance
From Exagen Inc.
Via GlobeNewswire
Exagen Inc. to Participate in the Canaccord Genuity 44th Annual Growth Conference
From Exagen Inc.
Via GlobeNewswire
Exagen Appoints Jeffrey G. Black as New Chief Financial Officer
From Exagen Inc.
Via GlobeNewswire
Exagen Inc. (NASDAQ: XGN) Near the Top of Equities by Percentage Gain on 1/29
Via Investor Brand Network
Exagen to Announce Second Quarter 2024 Results on August 5, 2024
From Exagen Inc.
Via GlobeNewswire
Exagen Inc. Reports Strong First Quarter 2024 Results: Raises Guidance for Full Year
From Exagen Inc.
Via GlobeNewswire
Exagen Announces Campaign for Lupus Awareness Month
From Exagen Inc.
Via GlobeNewswire
Exagen to Announce First Quarter 2024 Results on May 13, 2024
From Exagen Inc.
Via GlobeNewswire
Exagen Inc. Announces Changes to the Board of Directors
From Exagen Inc.
Via GlobeNewswire
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results
From Exagen Inc.
Via GlobeNewswire
Exagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
From Exagen Inc.
Via GlobeNewswire
Exagen to Announce Fourth Quarter 2023 and Full-Year Financial Results on March 18, 2024
From Exagen Inc.
Via GlobeNewswire
Exagen Inc. to Participate in the 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
From Exagen Inc.
Via GlobeNewswire
Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance
From Exagen Inc.
Via GlobeNewswire
Exagen Inc. Reports Strong Third Quarter 2023 Results
From Exagen Inc.
Via GlobeNewswire
Exagen Inc. and Johns Hopkins University Announce License Agreement for Novel Patented Lupus Nephritis Biomarkers
From Exagen Inc.
Via GlobeNewswire
Exagen Inc. to Participate in the 2023 Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
From Exagen Inc.
Via GlobeNewswire
Exagen to Announce Third Quarter 2023 Financial Results on November 13, 2023
From Exagen Inc.
Via GlobeNewswire
Exagen Announces Acceptance of Multiple Abstracts at ACR 2023 Annual Meeting
From Exagen Inc.
Via GlobeNewswire
Exagen Inc. to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
From Exagen Inc.
Via GlobeNewswire
Exagen Inc. Reports Strong Second Quarter 2023 Results
From Exagen Inc.
Via GlobeNewswire
Exagen Inc. to Participate in the Canaccord Genuity 43rd Annual Growth Conference
From Exagen Inc.
Via GlobeNewswire
Exagen to Announce Second Quarter 2023 Financial Results on August 7, 2023
From Exagen Inc.
Via GlobeNewswire
Exagen Inc. Appoints Paul Kim to Board of Directors
From Exagen Inc.
Via GlobeNewswire
Exagen Inc. to Participate in the William Blair 43rd Annual Growth Stock Conference
From Exagen Inc.
Via GlobeNewswire
Exagen Inc. Reports First Quarter 2023 Results
Record Physician Demand for AVISE® CTD 
From Exagen Inc.
Via GlobeNewswire
Exagen Announces Campaign for Lupus Awareness Month
From Exagen Inc.
Via GlobeNewswire
Exagen to Announce First Quarter 2023 Financial Results on May 15, 2023
From Exagen Inc.
Via GlobeNewswire
Exagen Inc. Reports Fourth Quarter and Full Year 2022 Results
Record AVISE® CTD Volume in 2022 
From Exagen Inc.
Via GlobeNewswire
Exagen to Announce Fourth Quarter and Full Year Financial Results on March 20, 2023
From Exagen Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.